Hengrui Pharma Disclosed Saturday August 22, 2026 That China's Center for Drug Evaluation (CDE) Granted Implied License for HRS-4729 in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Hepatitis, Extending Hengrui's Cardiometabolic Pipeline Beyond Its Existing Ribupatide (GLP-1/GIP/Glucagon Triple Agonist Licensed Ex-China to Kailera Therapeutics for Global Phase 3 in H1 2027) Into the Growing MASH Commercial Category That Is Anchored Commercially by Madrigal Pharmaceuticals' Rezdiffra (Resmetirom, First MASH Drug Approved March 2024) and Novo Nordisk's Wegovy (Semaglutide 2.4 mg, First GLP-1 Receptor Agonist Approved for MASH in August 2025); The Hengrui CDE Implied License Provides Approval to Initiate Human Clinical Trials in China Under a Simplified Regulatory Pathway
Hengrui Pharma disclosed Saturday August 22, 2026 that China's Center for Drug Evaluation (CDE) granted implied license for HRS-4729 in metabolic dysfunction-associated fatty liver disease (MAFLD) and hepatitis. The CDE implied license is a Chinese regulatory instrument that provides approval to initiate human clinical trials in China under a simplified pathway (similar in function to a US Investigational New Drug application, though procedurally different). HRS-4729's specific molecular mechanism has not been publicly disclosed in detail; the MAFLD/hepatitis indication placement suggests likely mechanisms include FGF21 analog, thyroid hormone receptor beta agonist, or a novel liver-target mechanism. The disclosure extends Hengrui's cardiometabolic pipeline beyond its existing ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist licensed ex-China to Kailera Therapeutics for global Phase 3 initiation in H1 2027) into the growing MASH commercial category. MASH commercial market context: the category is anchored by Madrigal Pharmaceuticals' Rezdiffra (resmetirom, a thyroid hormone receptor beta agonist and the first FDA-approved MASH drug, approved March 2024) and Novo Nordisk's Wegovy (semaglutide 2.4 mg received FDA accelerated approval for non-cirrhotic MASH with moderate-to-advanced fibrosis in August 2025). The Hengrui advance into MAFLD/hepatitis positions the company for a potential fourth cardiometabolic franchise beyond obesity, type 2 diabetes, and cardiovascular disease.